Iberdomide (Synonyms: CC-220)

Name: Iberdomide
Brand: MedChemExpress
SKU: HY-101291
Rating: 5.0 (11 reviews)

Cat. No.: HY-101291 Purity: 99.54%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Iberdomide (CC-220) is an orally active and potent cereblon (CRBN) E3 ligase modulator (CELMoD) with an IC₅₀ of ~150 nM for cereblon-binding affinity. Iberdomide, a derivative of Thalidomide (HY-14658), has antitumor and immunostimulatory activities.

For research use only. We do not sell to patients.

CAS No. : 1323403-33-3

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
2 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 11 publication(s) in Google Scholar

Other Forms of Iberdomide:

Iberdomide (Standard) Get quote

11 Publications Citing Use of MCE Iberdomide

Cell Proliferation/Viability Assay

Bio/Physico-chemical Assay

ELISA

: Iberdomide purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2022 May;3(5):595-613. [Abstract]; Western blot analysis for IKAROS, CK1α and MENIN protein following treatment of MV4;11 human MLL-r AML cell line for 5 hours with increasing doses of Thalidomide, lenalidomide, Pomalidomide and iberdomide (10,100, 1000 nM), using ACTIN as a loading control.

: Iberdomide purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Sep 10;13(1):5324. [Abstract]; Western immunoassays used to monitor changes in BNC2 levels in LX2 cells treated with 1 μM pomalidomide (Pom.), thalidomide (Thal.), CC-885, Iberdomide (Iber.) or vehicle for 24 h.

: Iberdomide purchased from MedChemExpress. Usage Cited in: J Proteome Res. 2022 Aug 5;21(8):1842-1856. [Abstract]; MM1S, HL60, and HCT116 cells were treated with 10 μM Lenalidomide, Pomalidomide, Avadomide, Iberdomide, CC-92480, CC-90009, CC-885, or DMSO as controls, respectively, and proteomics analysis was performed.

: Iberdomide purchased from MedChemExpress. Usage Cited in: J Proteome Res. 2022 Aug 5;21(8):1842-1856. [Abstract]; Clustering of the protein abundance changes (drug/DMSO, log2) in three cell lines separated the compounds into two proteomic drug clusters: cluster1 (Lenalidomide, Pomalidomide, Avadomide, Iberdomide, CC-92480) that degrades C2H2 zinc finger proteins, and cluster2 (CC-90009 and CC-885) that degrades translation termination proteins GSPT1 and GSPT2.

: Iberdomide purchased from MedChemExpress. Usage Cited in: Blood Cancer J. 2019 Feb 11;9(2):19. [Abstract]; lenalidomide-sensitive human papillomavirus (HMCL) cell lines (MM.1S, KMS11, XG1, and OPM2) in the presence of lenalidomide. The responses of these derived cell lines to the more potent immunomodulatory agent CC-220 (0-1000 nM, 5 days) were then examined.

: Iberdomide purchased from MedChemExpress. Usage Cited in: Blood Cancer J. 2019 Feb 11;9(2):19. [Abstract]; The combination of SGC-CBP30 (0.2 and 0.4 μM, 5 days) and Lenalidomide (10 μM, 5 days) exerted substantial synergy in reducing the viability of myeloma XG1LenRes cells.

: Iberdomide purchased from MedChemExpress. Usage Cited in: Blood Cancer J. 2019 Feb 11;9(2):19. [Abstract]; Immunoblotting assays detected the changes in IRF4, MYC, and STAT3 after treatment with Lenalidomide （10 μM） or SGC-CBP30 (0.2 and 0.4 μM) alone or in combination (day 3).

: Iberdomide purchased from MedChemExpress. Usage Cited in: Blood Cancer J. 2019 Feb 11;9(2):19. [Abstract]; SGC-CBP30 (0.2 and 0.4 μM, 2 days) treatment also reduced autocrine IL-6 production in XG1LenRes cells, both in the absence and presence of Lenalidomide (10 μM, 2 days).

: Iberdomide purchased from MedChemExpress. Usage Cited in: Elife. 2018 Aug 1;7:e38430. [Abstract]; SK-N-DZ cells were treated with 0.1 µM CC-220, 1 µM dBET57, 1 µM pomalidomide (3× biological replicates), or DMSO as a control (3× biological replicates) for 5 h. Protein abundance from each experiment was analyzed using TMT quantification mass spectrometry (see Materials and methods for details).

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Ligands for E3 Ligase Isoform Specific Products:

View All Isoforms

von Hippel-Lindau (VHL) MDM2 Cereblon IAP KLHDC2 Fbxo3 RNF4 DCAF11 DCAF1 UHRF1 TRIM21 NEURL1B

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

Cereblon

Cellular Effect

Cell Line	Type	Value	Description	References
MM1.S	IC₅₀	13 nM Compound: CC-220	Antiproliferative activity against human MM1S cells measured after 168 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay Antiproliferative activity against human MM1S cells measured after 168 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay	[PMID: 31125896]
MV4-11	IC₅₀	> 20000 nM Compound: CC-220	Antiproliferative activity against human MV411 cells measured after 168 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay Antiproliferative activity against human MV411 cells measured after 168 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay	[PMID: 31125896]

In Vitro

Iberdomide (CC-220; 0.01, 0.1, 1, 10 μM; 72-96 hrs) has antiproliferative effects in a panel of multiple myeloma (MM) cell lines (EJM, H929, KMS11, KMS128M, KMS12PE, MM1.S, MM1.R, RPM-8226, U266 cells) across a range of concentrations^[1].
Iberdomide (0.1 μM; 96 hrs) induces apoptosis in all MM cell lines^[1].
Iberdomide (0.1 μM; 24, 48, 72 hrs) results in time-dependent increases in G0/G1 and sub-G1 cell cycle fractions on H929 cells^[1].
Iberdomide leads to rapid Aiolos depletion in the KMS12BM line^[1].
Iberdomide (0.1 μM) displays some anti-proliferative activity in two of the Pomalidomide-resistant (PR) lines with cereblon mutations (EJM/PR and H929/PR) along with decreased levels of cereblon protein^[1].
Iberdomide (0.1-1000 nM; 72 hrs) equally induces PBMC-mediated killing of both parental MM1.S cells and MM1.S/PR cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Iberdomide (CC-220; 10 mg/kg; oral gavage) after 6 or 24 hours causes higher hCRBN expression in hC343 splenocytes correlated to deeper IKZF1/3 downregulation in WT (C57BL/6), hC123, or-343, (representing two different transgenic founder lines expressing hCRBN) and mCrbn^-/- mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

449.50

Formula

C₂₅H₂₇N₃O₅

CAS No.

1323403-33-3

Appearance

Solid

Color

White to off-white

SMILES

O=C([C@@H](N(CC1=C2C=CC=C1OCC3=CC=C(CN4CCOCC4)C=C3)C2=O)CC5)NC5=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 175 mg/mL (389.32 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.2247 mL	11.1235 mL	22.2469 mL
5 mM	0.4449 mL	2.2247 mL	4.4494 mL
10 mM	0.2225 mL	1.1123 mL	2.2247 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.63 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.63 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (4.63 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.54%

Select Batch:

Data Sheet (280 KB) SDS (394 KB)

COA (252 KB) HNMR (259 KB) LCMS (93 KB)

Handling Instructions (2659 KB)

References

[1]. Chad C Bjorklund, et al. Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN. Leukemia. 2020 Apr;34(4):1197-1201. [Content Brief]

[2]. Erin W Meermeier, et al. Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy. Blood Cancer Discov. 2021 Jul;2(4):354-369. [Content Brief]

Kinase Assay
^[1]

Iberdomide is dissolved in DMSO. In the assay, 60 nM 6Xhis-tagged CRBN-DDB1 is combined with 30 nM cy5-conjugated cereblon modulator and 3 nM LanthaScreen Eu-anti-His Tag antibody in 20 mM HEPES pH 7, 150 mM NaCl, 0.005% Tween-20 assay buffer. FRET is observed by exciting at 340 nm and monitoring emission at 615 nm and 665 nm, and FRET efficiency is determined by the ratio of FRET to non-FRET emission. Competing cereblon modulating compound (Iberdomide) or DMSO carrier is titrated and incubated for 10 min before scanning^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References

[1]. Chad C Bjorklund, et al. Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN. Leukemia. 2020 Apr;34(4):1197-1201. [Content Brief]

[2]. Erin W Meermeier, et al. Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy. Blood Cancer Discov. 2021 Jul;2(4):354-369. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.2247 mL	11.1235 mL	22.2469 mL	55.6174 mL
	5 mM	0.4449 mL	2.2247 mL	4.4494 mL	11.1235 mL
	10 mM	0.2225 mL	1.1123 mL	2.2247 mL	5.5617 mL
	15 mM	0.1483 mL	0.7416 mL	1.4831 mL	3.7078 mL
	20 mM	0.1112 mL	0.5562 mL	1.1123 mL	2.7809 mL
	25 mM	0.0890 mL	0.4449 mL	0.8899 mL	2.2247 mL
	30 mM	0.0742 mL	0.3708 mL	0.7416 mL	1.8539 mL
	40 mM	0.0556 mL	0.2781 mL	0.5562 mL	1.3904 mL
	50 mM	0.0445 mL	0.2225 mL	0.4449 mL	1.1123 mL
	60 mM	0.0371 mL	0.1854 mL	0.3708 mL	0.9270 mL
	80 mM	0.0278 mL	0.1390 mL	0.2781 mL	0.6952 mL
	100 mM	0.0222 mL	0.1112 mL	0.2225 mL	0.5562 mL

Iberdomide Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Iberdomide (Synonyms: CC-220)

Customer Review

Other Forms of Iberdomide:

Iberdomide Related Antibodies

11 Publications Citing Use of MCE Iberdomide

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Ligands for E3 Ligase Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Iberdomide Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Iberdomide Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report